Merck & Co. is handing over $200 million to China ... in combination with the VEGFR inhibitor rivoceranib for the first-line treatment of liver cancer. But recent months had brought better ...

USW Local 10-00086 president said Merck has offered "the worst set of proposals ever" during collective bargaining ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional ...